vs
Side-by-side financial comparison of Osisko Development Corp. (ODV) and Silence Therapeutics plc (SLN). Click either name above to swap in a different company.
Silence Therapeutics plc is the larger business by last-quarter revenue ($15.7M vs $10.4M, roughly 1.5× Osisko Development Corp.).
Osisko Development Corp. is a Canada-based mining exploration and development firm focused on high-grade gold and precious metal assets. It holds North American mineral projects, advancing them through exploration, feasibility study, and pre-production phases while adhering to sustainable mining standards.
Silence Therapeutics is a London-based pharmaceutical company formed in 1994. The company has pioneered the development of short-interfering ribonucleic acid (siRNA) therapeutics for the treatment of rare diseases. Silence Therapeutics has offices in London, New Jersey, and Berlin, with its corporate headquarters located in Hammersmith, London.
ODV vs SLN — Head-to-Head
Income Statement — Q3 FY2024 vs Q1 FY2024
| Metric | | |
|---|---|---|
| Revenue | $10.4M | $15.7M |
| Net Profit | — | $-2.3M |
| Gross Margin | 3.2% | 82.2% |
| Operating Margin | -149.3% | -35.6% |
| Net Margin | — | -14.7% |
| Revenue YoY | — | — |
| Net Profit YoY | — | — |
| EPS (diluted) | — | $-0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 24 | $10.4M | — | ||
| Q2 24 | $10.8M | — | ||
| Q1 24 | — | $15.7M | ||
| Q2 23 | $22.0M | — | ||
| Q3 22 | $4.7M | — |
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $-2.3M | ||
| Q2 23 | $-23.8M | — | ||
| Q3 22 | $-76.8M | — |
| Q3 24 | 3.2% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 82.2% | ||
| Q2 23 | 28.2% | — | ||
| Q3 22 | — | — |
| Q3 24 | -149.3% | — | ||
| Q2 24 | -124.0% | — | ||
| Q1 24 | — | -35.6% | ||
| Q2 23 | -241.5% | — | ||
| Q3 22 | -1940.8% | — |
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -14.7% | ||
| Q2 23 | -108.2% | — | ||
| Q3 22 | -1641.7% | — |
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $-0.02 | ||
| Q2 23 | — | — | ||
| Q3 22 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $156.8M |
| Total Assets | — | — |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $156.8M | ||
| Q2 23 | — | — | ||
| Q3 22 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-9.1M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $-9.1M | ||
| Q2 23 | — | — | ||
| Q3 22 | — | — |
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.0% | ||
| Q2 23 | — | — | ||
| Q3 22 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
